A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61P 35/00 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2560862
The use of a cancerous disease modifying antibody (CDMAB) 11 BD-2E11-2 for treating a tumor in humans and methods of isolating and identifying cancerous cells which express a melanoma-associated chondroitin sulfate proteoglycan (MCSP) antigenic moiety. The monoclonal antibody 11 BD-2E11-2 (ATCC accession number PTA-5643), which binds a MCSP antigenic moiety, is cytotoxic to cancer cells which express the antigenic moiety. The monoclonal antibody 11 BD-2E11-2 is useful for delaying the disease progression of a human tumor.
L'invention porte sur l'utilisation d'un anticorps modificateur des cellules cancéreuses (CDMAB) 11 BD-2E11-2 pour traiter une tumeur chez l'homme et sur des procédés d'isolement et d'identification de cellules cancéreuses qui expriment un fragment antigène de MCSP (protéoglycane de sulfate de condroïtine associé à un mélanome). L'anticorps monoclonal 11 BD-2E11-2 (au numéro d'accession ATCC: PTA-5643), qui se fixe à un fragment antigène de MCSP à une action cytotoxique sur les cellules cancéreuses exprimant le fragment antigène. L'anticorps monoclonal 11 BD-2E11-2 retarde la progression de la maladie causée par les tumeurs humaines.
Ferry Alison L.
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Arius Research Inc.
F.hoffmann-La Roche Ag
Gowling Lafleur Henderson Llp
LandOfFree
Cytotoxicity mediation of cells evidencing surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxicity mediation of cells evidencing surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxicity mediation of cells evidencing surface... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1385985